Memorial Sloan-Kettering Cancer CenterのEmily Cheng 研究室では、現在Postdoctoral Fellow を数名募集しております。当研究室では、BCL-2ファミリーによるアポトーシス制御機構の解明、及びBCL-2ファミリーを標的とした新規癌治療法の確立を目指して研究をおこなっています。応募される方は、以下の英文広告をご参照の上、Dr. ChengまでCV及び推薦者3名の連絡リストをお送りください。なお、日本語でのご質問等ございましたら、当研究室出身の山内茜(akaneyamauchi@hotmail.com)までお気軽にお問合せ下さい。
-------
Postdoctoral positions are available for highly motivated individuals interested in studying the BCL-2 family and the fundamental mechanisms of cell death, the impact of cell death regulators in tumorigenesis and response to anticancer therapy, developing novel therapeutics targeting the BCL-2 family, and translating cell death mechanisms into targeted cancer therapy (Science 330: 1390-1393; Molecular Cell 36: 487-499; Nature Cell Biology 8:1348-1358; Science Signaling 6:ra20; Cancer Cell 25, 530–542; Nature Cell Biology 17:1270-1281). We are particularly interested in the pathogenesis and targeted therapy of lung cancer, mechanisms of resistance to targeted therapy, and how to overcome resistance to targeted therapy.

Applicants should hold a Ph.D. degree and have a strong background in molecular/cellular biology, biochemistry, mouse genetics, or cancer biology, and a good publication record.

Full applications including curriculum vitae and a list of three references should be submitted through chengpostdocapps@gmail.com to: Emily Cheng, M.D., Ph.D., Associate Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.